CCO Management Series
Choosing an Initial Protease Inhibitor for PI-Naive Patients
When to Use the First PI-Based Regimen
|
Module 1 of 2
|
Program Director:
Kimberly Y. Smith, MD, MPH
|
|
 John A. Bartlett, MD, discusses the criteria for choosing between PI-based and NNRTI-based regimens in first-line therapy Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss clinical trial data that support the use of efavirenz and lopinavir/ritonavir in initial regimens for the treatment of antiretroviral-naive patients
- Describe the findings of ACTG study 5142, a head-to-head comparison of lopinavir/ritonavir vs efavirenz for first-line treatment of antiretroviral-naive patients
- List criteria other than efficacy that may affect the choice of regimen for initial treatment of antiretroviral-naive patients
|
The Choice of Protease Inhibitor for the Initial PI-based Regimen
|
Module 2 of 2
|
Program Director:
Kimberly Y. Smith, MD, MPH
|
|
Ian Frank, MD, discusses current thinking regarding appropriate selection of protease inhibitors for use in first-line antiretroviral therapy or second-line following failure on a NNRTI- or NRTI-based regimen. Learning Objectives
Upon completion of this activity, participants should be able to:
- List the preferred and alternative choices for initial PI regimens
- Review the efficacy data supporting use of each PI as part of initial PI regimen
- Discuss the roles of convenience, safety, tolerability, and resistance in choosing an initial PI regimen
|
Interactive Case Challenges
Management of an HIV-infected, Treatment-Naive, Vietnam War Veteran With a History of Poorly Controlled Paranoid Schizophrenia
Program Director:
Kimberly Y. Smith, MD, MPH
|
|
 John A. Bartlett, MD, explores the case management of a treatment-naive schizophrenic Vietnam War veteran who presents with advanced HIV infection, a history of intravenous drug use, marginal housing, and a history of inconsistent follow-up with his healthcare. Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain the differences between and the use of genotype and phenotype HIV drug resistance assays
- Discuss the use of antiretroviral drugs in psychiatric HIV patients
- Review the use of PIs in the treatment of antiretroviral-naive HIV-infected patients
|
Management of a Patient With Virologic Failure on His Initial NNRTI-Based Triple-Therapy
Program Director:
Kimberly Y. Smith, MD, MPH
|
|
Paul E. Sax, MD, discusses management of an HIV/HCV-coinfected patient following treatment failure. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the role of HIV resistance testing in the choice of a new regimen following treatment failure
- Discuss hepatotoxicity in the context of antiretroviral treatment for HIV infection
- Review the use of ritonavir to boost PIs
|
Choice of an Initial PI for a Patient With Hypertension and NNRTI Resistance
Program Director:
Kimberly Y. Smith, MD, MPH
|
|
Ian Frank, MD, discusses issues related to PI use in the face of NNRTI resistance and cardiovascular risk in a middle-aged male patient. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the role of cardiovascular risk factors in planning antiretroviral therapy for HIV-infected patients
- Review the use of lipid-lowering drugs vs antiretroviral modification for management of dyslipidemia in HIV-infected patients
- Describe how baseline resistance may modify the options available for antiretroviral therapy
|
CCO Slidesets
Choosing an Initial Protease Inhibitor for PI-Naive Patients
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 3,433 KB
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Medical Education Collaborative and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|